Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06PFT
|
|||
| Former ID |
DCL000622
|
|||
| Drug Name |
Rhumab Beta7
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 3 | [1] | |
| Company |
Roche; Genentech
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026082) | |||
| REF 2 | A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013 Aug;62(8):1122-30. | |||
| REF 3 | Clinical pipeline report, company report or official report of Genentech (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.